imo-2125
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT00728936)
Timeline
Indications
Mechanism of action
- Toll-like receptor 9AGONIST
TLR9 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- imo-2125
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03445533 | Phase 3 | Feb 28, 2018 | Aceragen, Inc/, Bristol-Myers Squibb |
| NCT03052205 | Phase 1 | May 1, 2017 | Aceragen, Inc/ |
| NCT02644967 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2015 | Aceragen, Inc/ |
| NCT00990938 | Phase 1 | Sep 1, 2009 | Aceragen, Inc/ |
| NCT00728936 | Phase 1 | Sep 1, 2007 | Aceragen, Inc/ |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aceragen, Inc/ | For profit | 5 | 5 | 3 | 2007 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1